Clinical Trial

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Name: Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study — clinical trial record (NCT07398638)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a prospective, multicenter, open-label Phase Ib/II clinical study designed to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of lisatoclax in combination with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Trial Details

NCT Number	NCT07398638
Lead Sponsor	Sun Yat-sen University
Conditions	Diffuse Large B Cell Lymphoma (DLBCL)
Enrollment	122 participants
Start Date	2026-02-28
Primary Completion	2029-02-28 (estimated)
Study Completion	2031-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-02-10